Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts

PRAME-Directed TCR Cell Therapy Achieves Deep Remission in Pediatric Nephroblastoma Patient

- A 17-year-old patient with advanced metastatic nephroblastoma achieved deep remission following treatment with Immatics' PRAME-directed TCR T-cell therapy at KiTZ in Heidelberg. - The patient had rapidly progressing disease with brain, liver, and lung metastases and had exhausted all available treatment options before receiving the experimental therapy. - PET scan and MRI imaging demonstrated marked tumor regression across all lesion sites, with molecular remission confirmed by liquid biopsy showing no tumor-derived DNA. - The response remained ongoing at six months of follow-up, with the patient in excellent physical condition despite manageable cytokine release syndrome during treatment.